You are here: Home Published Research Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.

Gerhart Knerer, Afisi Ismaila, and David Pearce (2012)

Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.

Journal of medical economics, 15(1):61–76.

The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases that can have severe consequences. The health economic model presented here is intended to estimate the clinical and economic impact of vaccinating birth cohorts in Canada and the UK with the 10-valent, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared with the newly licensed 13-valent pneumococcal conjugate vaccine (PCV-13).

Adolescent, Adult, Aged, Bacterial Proteins, Canada, Carrier Proteins, Child, Child, Preschool, Cost-Benefit Analysis, Humans, Immunoglobulin D, Lipoproteins, Markov Chains, Middle Aged, Outcome Assessment (Health Care), United Kingdom, Vaccines, Conjugate, Young Adult
Adolescent, Adult, Aged, Bacterial Proteins, Canada, Carrier Proteins, Child, Child, Preschool, Cost-Benefit Analysis, Humans, Immunoglobulin D, Lipoproteins, Markov Chains, Middle Aged, Outcome Assessment (Health Care), United Kingdom, Vaccines, Conjugate, Young Adult
 
Document Actions